JP2002527478A - 精神分裂病を治療する方法、及びこの方法に使用するための手段 - Google Patents
精神分裂病を治療する方法、及びこの方法に使用するための手段Info
- Publication number
- JP2002527478A JP2002527478A JP2000576851A JP2000576851A JP2002527478A JP 2002527478 A JP2002527478 A JP 2002527478A JP 2000576851 A JP2000576851 A JP 2000576851A JP 2000576851 A JP2000576851 A JP 2000576851A JP 2002527478 A JP2002527478 A JP 2002527478A
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- pharmaceutically acceptable
- acceptable salt
- article according
- medical article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 20
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 57
- 229960002715 nicotine Drugs 0.000 claims abstract description 52
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 238000001671 psychotherapy Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940127554 medical product Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 20
- 239000010410 layer Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000126 substance Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000004547 Hallucinations Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000027534 Emotional disease Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- IOGOPUMIBWOQBJ-UHFFFAOYSA-N 2,2-dimethylpropanoic acid 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound C(C(C)(C)C)(=O)O.N1=CC=CC(=C1)C1N(C)CCC1 IOGOPUMIBWOQBJ-UHFFFAOYSA-N 0.000 description 1
- VWTHFJXLFGINSW-PPHPATTJSA-N 2-hydroxypropanoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CC(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 VWTHFJXLFGINSW-PPHPATTJSA-N 0.000 description 1
- DEQLKLBWMZRSHN-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;pentanoic acid Chemical compound CCCCC(O)=O.CN1CCCC1C1=CC=CN=C1 DEQLKLBWMZRSHN-UHFFFAOYSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000036755 Schizophrenia simple Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- CPCNAMNNSLASDC-UHFFFAOYSA-N acetic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(O)=O.CN1CCCC1C1=CC=CN=C1 CPCNAMNNSLASDC-UHFFFAOYSA-N 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940015769 nicotine chewing gum Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19847715.5 | 1998-10-16 | ||
| DE19847715A DE19847715A1 (de) | 1998-10-16 | 1998-10-16 | Verfahren zur Behandlung der Schizophrenie sowie Mittel zur Verwendung in diesem Verfahren |
| PCT/EP1999/007320 WO2000023077A1 (de) | 1998-10-16 | 1999-10-02 | Verfahren zur behandlung der schizophrenie sowie mittel zur verwendung in diesem verfahren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002527478A true JP2002527478A (ja) | 2002-08-27 |
Family
ID=7884666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000576851A Pending JP2002527478A (ja) | 1998-10-16 | 1999-10-02 | 精神分裂病を治療する方法、及びこの方法に使用するための手段 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1121126A1 (es) |
| JP (1) | JP2002527478A (es) |
| KR (1) | KR20010080135A (es) |
| CN (1) | CN1323210A (es) |
| AR (1) | AR020815A1 (es) |
| AU (1) | AU6199299A (es) |
| BR (1) | BR9914570A (es) |
| CA (1) | CA2341855A1 (es) |
| DE (1) | DE19847715A1 (es) |
| WO (1) | WO2000023077A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509705A (ja) * | 2003-10-28 | 2007-04-19 | アルザ・コーポレーシヨン | タバコ使用頻度を低下させる方法および装置 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10110953A1 (de) * | 2001-03-07 | 2002-09-19 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten |
| IL177071A0 (en) * | 2005-08-01 | 2006-12-10 | Nitto Denko Corp | Method of preparing a nicotine transdermal preparation |
| EP2706854A4 (en) * | 2011-05-09 | 2014-12-03 | Envivo Pharmaceuticals Inc | TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE |
| CZ309812B6 (cs) * | 2021-05-25 | 2023-11-01 | Consumer Brands International s.r.o | Směs pro výrobu nikotinových sáčků a způsob její výroby |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
| US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US5776956A (en) * | 1996-07-30 | 1998-07-07 | Lectec Corporation | Use of cotinine in treating psychiatric disorders |
| US5776957A (en) * | 1996-11-15 | 1998-07-07 | The University Of Kentucky Research Foundation | Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states |
-
1998
- 1998-10-16 DE DE19847715A patent/DE19847715A1/de not_active Withdrawn
-
1999
- 1999-10-02 WO PCT/EP1999/007320 patent/WO2000023077A1/de not_active Ceased
- 1999-10-02 KR KR1020017004649A patent/KR20010080135A/ko not_active Withdrawn
- 1999-10-02 EP EP99948923A patent/EP1121126A1/de not_active Ceased
- 1999-10-02 BR BR9914570-7A patent/BR9914570A/pt not_active IP Right Cessation
- 1999-10-02 AU AU61992/99A patent/AU6199299A/en not_active Abandoned
- 1999-10-02 CN CN99812210A patent/CN1323210A/zh active Pending
- 1999-10-02 CA CA002341855A patent/CA2341855A1/en not_active Abandoned
- 1999-10-02 JP JP2000576851A patent/JP2002527478A/ja active Pending
- 1999-10-14 AR ARP990105204A patent/AR020815A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509705A (ja) * | 2003-10-28 | 2007-04-19 | アルザ・コーポレーシヨン | タバコ使用頻度を低下させる方法および装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| AR020815A1 (es) | 2002-05-29 |
| AU6199299A (en) | 2000-05-08 |
| EP1121126A1 (de) | 2001-08-08 |
| CA2341855A1 (en) | 2000-04-27 |
| DE19847715A1 (de) | 2000-04-20 |
| CN1323210A (zh) | 2001-11-21 |
| WO2000023077A1 (de) | 2000-04-27 |
| BR9914570A (pt) | 2001-07-03 |
| KR20010080135A (ko) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU660336B2 (en) | Device for the transdermal administration of melatonin | |
| ES2367868T3 (es) | Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad. | |
| JP2755559B2 (ja) | 前脂肪細胞の分化を刺激する組成物と方法、およびこれに関連する治療処置方法 | |
| US8440671B2 (en) | Compositions comprising a phoshodiesterase-5 inhibitor and their use in methods of treatment | |
| Cleary | Transdermal delivery systems: a medical rationale | |
| US20190070396A1 (en) | Apparatus and methods for rapid transmucosal drug delivery | |
| EP1342489A1 (en) | Method of affecting sleep and sleep-related behaviors | |
| AU2008203320A1 (en) | Method for reducing acne or improving skin tone | |
| US20020151527A1 (en) | Method for reducing acne or improving skin tone | |
| US20020146469A1 (en) | Methods for reducing chronic stress in mammals | |
| JP2002527478A (ja) | 精神分裂病を治療する方法、及びこの方法に使用するための手段 | |
| KR20050119914A (ko) | 고기능 복합 패치형 구강 조성물 | |
| Mitrouska et al. | Pharmacological approaches to smoking cessation | |
| JPH09509139A (ja) | 酪酸エステル細胞分化薬 | |
| Thompson | Opioid peptides | |
| Pfeiffer | Potential of transdermal drug delivery in Parkinson’s disease | |
| DE19850517B4 (de) | Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall | |
| EP4159206A1 (en) | Long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of erectile dysfunction and benign prostatic hyperplasia | |
| CA2642581A1 (en) | Method for accelerating reentrainment of a circadian rhythm | |
| US20210186938A1 (en) | GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME | |
| Golding | Integrative Medicine Tools for Parkinson’s Disease Management | |
| Kaur et al. | Novel strategies for Neuro-Dysfunction management through Percutaneous Route: A Current Perspective. |